DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rituxan (Rituximab) - Current Clinical Trials

 
 



Rituxan Related Clinical Trials

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis [Completed]

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia [Completed]

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Active, not recruiting]

Rituximab to Treat Stiff Person Syndrome [Completed]

Rituximab for GVHD [Withdrawn]

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan [Recruiting]

Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab [Completed]

PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis [Recruiting]

A Study to Evaluate Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis [Completed]

A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma [Recruiting]

B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease [Not yet recruiting]

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease [Active, not recruiting]

Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma [Active, not recruiting]

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [Active, not recruiting]

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma [Active, not recruiting]

Rituxan With or Without Methotrexate in Psoriatic Arthritis [Completed]

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy [Recruiting]

Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan [Completed]

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients [Active, not recruiting]

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia [Active, not recruiting]

Multi-center Trial of Revlimid� and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) [Recruiting]

Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) [Recruiting]

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System [Recruiting]

Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma [Recruiting]

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma [Recruiting]

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies [Completed]

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia [Active, not recruiting]

Rituximab and ABVD for Hodgkin's Patients [Completed]

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]

Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma [Completed]

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma [Completed]

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas [Recruiting]

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant [Terminated]

Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis [Recruiting]

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma [Active, not recruiting]

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma [Recruiting]

Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma [Active, not recruiting]

Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]

Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP [Completed]

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Recruiting]

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD) [Terminated]

Bortezomib Plus Rituximab for EBV+ PTLD [Active, not recruiting]

Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT) [Completed]

Trial of Rituximab for Graves' Ophthalmopathy [Completed]

Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma [Recruiting]

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas [Recruiting]

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis [Completed]

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia [Completed]

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate [Completed]

A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma [Completed]

Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) [Active, not recruiting]

Alemtuzumab + Rituximab Consolidation in CLL [Terminated]

A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL [Active, not recruiting]

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline [Completed]

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) [Terminated]

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis [Active, not recruiting]

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma [Completed]

A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis [Completed]

B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study. [Recruiting]

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy [Recruiting]

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Active, not recruiting]

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia [Terminated]

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) [Completed]

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Recruiting]

A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate [Completed]

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation [Active, not recruiting]

Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation [Terminated]

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [Active, not recruiting]

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia [Completed]

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma [Recruiting]

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus [Completed]

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Completed]

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients [Recruiting]

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab [Completed]

A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) [Active, not recruiting]

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma [Recruiting]

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma [Completed]

Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-Matched Related HSCT [Completed]

Alemtuzumab and Rituximab in Aplastic Anemia [Withdrawn]

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma [Completed]

Rituxan in Churg Strauss Syndrome With Renal Involvement [Terminated]

Rituximab Trial for Pediatric Nephrotic Syndrome [Recruiting]

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Active, not recruiting]

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Active, not recruiting]

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) [Recruiting]

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Terminated]

Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma [Recruiting]

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) [Active, not recruiting]

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL [Active, not recruiting]

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma [Recruiting]

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL [Recruiting]

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Terminated]

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS [Completed]

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma [Terminated]

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015